| Project/Area Number |
17016087
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East |
|---|
Principal Investigator |
松村 保広 National Cancer Center Research Institute and Research Center for Innovative Oncology, National Cancer Center Hospital East, がん治療開発部, 部長 (90209619)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
眞鍋 史乃 独立行政法人, 理化学研究所中央研究所, 研究員 (60300901)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥47,400,000 (Direct Cost: ¥47,400,000)
Fiscal Year 2009: ¥9,600,000 (Direct Cost: ¥9,600,000)
Fiscal Year 2008: ¥9,600,000 (Direct Cost: ¥9,600,000)
Fiscal Year 2007: ¥9,600,000 (Direct Cost: ¥9,600,000)
Fiscal Year 2006: ¥9,600,000 (Direct Cost: ¥9,600,000)
Fiscal Year 2005: ¥9,000,000 (Direct Cost: ¥9,000,000)
|
|---|
| Keywords | ナノ材料 / 分子認識 / 医療・福祉 / 癌 / 薬理学 / ミセル / タキソール / SN-38 / CPT-1 / VEGF / NK105 / NK102 / 遺伝子デリバリー / CPT-11 / CPR-11 |
|---|
| Research Abstract |
Polymeric micelles are expected to increase the accumulation of drugs in tumor tissues utilizing the EPR effect and to incorporate various kinds of drugs into the inner core with relatively high stability. The size of the micelles can be controlled within the diameter range of 20 to 100nm, to ensure that the micelles do not pass through normal vessel walls ; therefore, a reduced incidence of the adverse effects of the drugs may be expected. There are several anticancer agent-incorporated micelle carrier systems under clinical evaluation after our preclinical evaluation of them.
Secondly, we developed a new cytotoxic immunoconjugates using a specially raised monoclonal antibody (mAb) to the tumor stroma. These newly developed immunoconjugates selectively extravasated from leaky tumor vessels, bound to the tumor stromal component ensleeving tumor vessels and created a scaffold, from which effective sustained release of a time-dependent anti-cancer agent occurred. This released anti-cancer agent subsequently diffused throughout the tumor tissue causing marked arrest of tumor growth. Cancer stromal targeting (CAST) therapy, utilizing a cytotoxic agent conjugated to a mAb directed at a specific inert constituent of the tumor stroma is thus validated as a highly effective new modality of oncological therapy.
|
